A pilot study of central venous catheter survival in cancer patients using low‐molecular‐weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)

Managing thrombosis in cancer patients

“…Primary thromboprophylaxis has not been shown to be beneficial and therefore is not routinely recommended 66. At least one cohort study of cancer patients with catheter‐associated thrombosis suggests that many patients can be treated with anticoagulation and leaving the catheter in place 67. The optimal type and duration of anticoagulation are unclear.…”

“…The CATHETER study enrolled 74 patients with CRT treated with dalteparin bridged to warfarin. At 3 months, the risk of major bleeding was 4% with no recurrent VTE, with a line preservation rate of 100% 67. The CATHETER 2 study further explored the use of DOAC in this condition.…”

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban

“…There is little prospective data and limited clinical trials on appropriate anticoagulation management of CVC thrombosis. However, low molecular weight heparin (LMWH) has been recommended and routine removal of the CVC has not been recommended 1, 2, 3, 4, 5. There are no data available yet about the use of rivaroxaban for CVC‐UEDVT.…”

“…Our cohort study does not lend itself to direct comparisons with previous reports. With that limitation in mind, in the previously published Catheter Study of LMWH followed by warfarin, the overall rate of CVC line removal was 43% 3.…”

“…Major bleeding events occurred in two patients treated with rivaroxaban, with an estimate of 2.4%. In The Catheter Study and the upper‐Extremity DVT arm of the RIETE trial, major bleeding was reported in 10.9% and 2.1%, respectively 3, 6.…”